Twist Bioscience (FRA:0ME) Debt-to-EBITDA : -0.66 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Twist Bioscience Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Twist Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €13.6 Mil. Twist Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €70.7 Mil. Twist Bioscience's annualized EBITDA for the quarter that ended in Dec. 2023 was €-127.3 Mil. Twist Bioscience's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.66.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Twist Bioscience's Debt-to-EBITDA or its related term are showing as below:

FRA:0ME' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.54 Med: -0.28 Max: -0.08
Current: -0.53

During the past 8 years, the highest Debt-to-EBITDA Ratio of Twist Bioscience was -0.08. The lowest was -0.54. And the median was -0.28.

FRA:0ME's Debt-to-EBITDA is ranked worse than
100% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.005 vs FRA:0ME: -0.53

Twist Bioscience Debt-to-EBITDA Historical Data

The historical data trend for Twist Bioscience's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Twist Bioscience Debt-to-EBITDA Chart

Twist Bioscience Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.08

-0.27

-0.44

-0.45

-0.54

Twist Bioscience Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.64	-0.44	-0.48	-0.62	-0.66

Competitive Comparison of Twist Bioscience's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Twist Bioscience's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Twist Bioscience's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Twist Bioscience's Debt-to-EBITDA falls into.

Twist Bioscience Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Twist Bioscience's Debt-to-EBITDA for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(13.958	+	74.185)	/	-163.179
	=	-0.54

Twist Bioscience's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(13.579	+	70.673)	/	-127.34
	=	-0.66

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Twist Bioscience (FRA:0ME) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Twist Bioscience Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Twist Bioscience's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Twist Bioscience (FRA:0ME) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Twist Bioscience Corp (FRA:0ME) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

TWST:USA 0ME:Germany

Address

681 Gateway Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.twistbioscience.com

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.

Twist Bioscience (FRA:0ME) Headlines

No Headlines